Assays

Identify, control, and prevent the spread of CPO

The BD MAX™ Check-Points CPO assay provides direct detection of carbapenemase-
producing organisms (CPO) for improved patient management and infection control

Challenge of carbapenem resistance

Effective screening controls the spread

Improving screening efficiency

The European CDC states that pathogens resistant to carbapenems are one of the biggest threats to patient safety¹
A large proportion of carbapenem-resistant Enterobacteriaceae (CRE) infections currently lack effective and relatively safe antibiotic treatment options²
CRE patients are 3 times more likely to receive inappropriate empiric therapy than non-CRE patients (46.5% vs 11.8%) resulting in longer hospital stays and increased system cost³
Carbapenemase genes KPC and OXA-48 were found most frequently in carbapenemase resistant Klebsiella pneumoniae and Escherichia coli⁴

Screening for colonisation is a key component of CPO control⁵

<strong>Screening for colonisation is a key component of CPO control<sup>5</sup></strong>

Active surveillance can reduce transmission of CPO in healthcare settings^6,7

Screening hospital inpatients for CPO can be cost-effective and even cost-saving⁷

Hospitals in the Netherlands and UK have estimated the economic impact of an out-break in their facilities to be approximately €1,000,000^8,9

The European Centre for Disease Prevention and Control recommends investing while prevalence is low, as once an endemic situation is reached, it is more costly and less effective¹⁰

BD MAX™ Check-Points CPO assay is an integrated molecular screening solution

Provides results for the five most common carbapenemase genes in Gram-negative bacteria
Test can be processed from rectal swabs

KPC

OXA-48*

NDM

VIM/IMP

* OXA-48 and OXA-48 like

Results in <2.5 hours compared to culture which can take up to 48 hours
Fully integrated on the BD MAX™ System, a fully automated molecular system capable of running BD and partner developed assays as well as laboratory-developed tests

Improved patient
management

Workflow
efficiency

Fast screening
results

BD MAX™ Check-Points CPO assayis part of the BD MAX™ Portfolio of HAI assays

BD MAX™
MRSA XT

BD MAX™
StaphSR

BD MAX™
Check-Points CPO

BD MAX™
Cdiff

VIASURE VanR Real
Time PCR Detection
Kit for BD MAX™

CPO, Carbapenemase-Producing Organisms; CRE, carbapenem-resistant Enterobacteriaceae; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; VIM, Verona integron-encoded metallo-β-lactamase.

1. World Health Organization. Infection prevention and control; 2017. Available at: http://www.who.int/infection-prevention/publications/guidelines-cre/en/. Updated 2017, Accessed May 2020. 2. David S et al. Nat Microbiol. 2019;4:1919–29. 3. Grundmann H et al. Lancet Infect Dis. 2017;17:153–63. 4. Zilberberg M et al. BMC Infect Dis. 2017;17(1):279. 5. Banerjee R, Humphries R. Virulence. 2017;8(4):427-439. 6. Antonelli A et al. Diagn Microbiol Infect Dis. 2016;86(1):30-34. 7. Lapointe-Shaw L, et al. Eur J Clin Microbiol Infect Dis. 2017;36(6):1047-1055. 8. Mollers M et al. Emerg Infect Dis. 2017;23(9):1574-1576. 9. Otter JA et al. Clin Microbiol Infect. 2017;23(3):188-196. 10. European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacteriaceae; 2006. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/carbapenem-resistant-enterobacteriaceae-risk-assessment-april-2016.pdf. Updated April 2016, Accessed May 2020.